Chief Executive Officer
Darin Hammers has served as Chief Executive Officer of the Company since September 2018. Mr. Hammers’ experience includes over 25 years of increasing leadership roles in Gynecology and Urology. Prior to joining DYSIS, he served as the President and CEO of Cogentix Medical which was acquired by Laborie in April of 2018. He joined Cogentix’s predecessor company Uroplasty as Vice President of Global Sales in January 2013 and was promoted to Chief Operating Officer prior to being named interim President and CEO in May 2016, and President and CEO in July 2016. Prior to joining Uroplasty, Mr. Hammers was Vice President of Sales for Bard Medical Division of C.R. Bard based in Covington, GA, focused on Urology care products. Prior to that, Mr. Hammers spent more than 12 years with Boston Scientific in various sales leadership positions in the Urology/Gynecology areas.
Casper Breum was previously CEO of ilochip A/S, a venture backed company focused on development of diagnostic biochips. Before this he held different positions at H.Lundbeck A/S most recently in corporate business development and strategy where he gained broad international experience. He was also a member of the Board of Directors of the Lundbeck Foundation and Lundbeckfond Invest as an employee representative. Prior to his work at H.Lundbeck, Casper worked for Novo Nordisk A/S and Niels Clauson-Kaas A/S. Casper has an MSc in organic chemistry and an MBA.